Beyond Adagrasib and Lumakras, Roche's GDC-6036's phase I data are also scheduled to be presented at ESMO 2022.

Early stage results of GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation

Sep 08, 2022 | DelveInsight

Roche (Genentech) will present new data supporting its GDC-6036 monotherapy in patients with solid tumors with a KRASG12C mutation. This oral, highly potent, and selective KRAS G12C inhibitor irreversibly locks the protein in an inactive state to turn off its oncogenic signaling. Preclinical studies showed that GDC-6036 was more potent and selective in vitro compared with sotorasib (LUMAKRAS) and adagrasib (MRTX849). Data presented earlier at the 2022 World Conference on Lung Cancer GDC-6036 showed promising responses and safety with the monotherapy in patients with previously treated KRASG12C–mutant NSCLC. However, the market is currently getting crowded with many industry projects targeting KRAS in case of solid tumors. An update on this data will be important to inform if GDC-6036 shows positive safety responses and whether it can prove its potential when compared to other KRAS drugs in development.


Trial Acronym



Abstract number

Date/Time (CEST)

KRYSTAL-1: updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation



Colorectal Cancer


12/9/2022 from 10:15 AM to 10:25 AM

Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation



Solid Tumors


12/9/2022 from 5:20 PM to 5:25 PM

Sotorasib in combination with panitumumab in refractory KRAS G12C mutated colorectal cancer: safety and efficacy for phase 1b full expansion cohort

CodeBreaK 101


Colorectal Cancer


12/9/2022 from 10:25 AM to 10:35 AM

Get more insights, at: Non-small cell lung cancerColorectal Cancer, Pancreatic Cancer, and Endometrial Cancer

Recent Article